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LIST OF ABBREVATIONS USED
PCO - Polycystic ovary
PCOS - Polycystic ovary syndrome
TVS - Trans vaginal sonograpny
TAS - Trans abdominal sonography
LH - Leutinizing hormone
FSH - Follicle stimulating hormone
NIH - National Institute of Health
USG - Ultrasonography
BMI - Body mass index
F-G Score - Ferriman – Gallwey Score
HDL - High densitylipoprotein
CAH - Congenital adrenal hyperplasia
ACTH - Adrenocorticortropic hormone
17OHP - 17 hydroxy progesterone
RIA - Radio immunoassay
OCP - Oral Contraceptive pill
SHBG - Sex hormone binding globulin
DHEAS - Dehydroepiandrosterone sulphate
GnRH - Gonadotropin releasing hormone
1INTRODUCTION
Most common female endocrinopathy affecting the reproductive
age group is polycystic ovary syndrome. It is a heterogenous disorder. It
is associated with menstrual disorder, infertility, obesity, hirsutism and
insulin resistance. It may vary from mild to severe disturbance of
endocrine, reproductive and metabolic function.
It may lead to infertility, endocrine disorder and long term health
environmental factors. The molecular biology and bioinformatics have
helped better understanding of PCOS. PCOS is usually diagnosed by
clinical history or physical findings. Laboratory findings are important
to differentiate other conditions resembling of PCOS.
Normal healthy women have classic ultrasound appearance of
polycystic ovaries without symptoms. We have to differentiate between
PCOS with symptoms and PCOS without symptoms.
2AIMS AND OBJECTIVES
? To analyse various clinical presentation of PCOS in population in
North Chennai.
? To establish the role of  hormonal assay in diagnosing PCOS.
? To understand the correlation between clinical and endocrine
changes with PCOS.
3REVIEW OF LITERATURE
                                  Figure 1: Polycystic Ovaries
Definition
A meeting was conducted recently by European society of Human
Reproduction and Embryology regarding the redefinition of PCOS,
which was agreed  by Rotterdam consensus group 2003. It said that all
clinicians and investigators should  use this internationally agreed
definition to be uniform in research and routine clinical management.
4Meeting recommended at least two of the following 3 criteria in
diagnosing PCOS.
1. Oligomenorrhoea / Anovulation
2. Laboratory finding / Clinical Findings suggestive of
hyperandrogenism
3. Direct Inspection of polycystic ovaries by ultrasound. Other
aetiologies  for hyperandrogenism ruled out Eg: Cogential adrenal
hyperplasia,Cushing’s  syndrome or Androgen -secreting tumours
.
Androgen excess and PCOs Society (AE-PCOS) specified
similar  set  of  criteria  for  diagnosis  of   PCOs  .They  said  that  PCOs
should be primarily a disorder of androgen excess or hyperandrogenism.
The clinical criteria set forward as
1. Presence of hyperandrogenism (Clinical/Biochemical)
2. Ovarian dysfunction (Oligoanovulation/Polycystic ovaries)
3. Exclusion of related disorders.
5NIH Criteria:
         In 1990 a consensus workshop sponsored by NIH/NICHD
suggested that a person has PCOs if they have all the following criteria
1. Oligoovulation
2. Signs of androgen excess
3. Exclusion of other disorder that can result in menstrual
irregularity and hyperandrogenism
NIH 1990 ROTTERDAM 2003 AES 2006
MUST INCLUDE
ALL
1.Chronic Anovulation
2.Clinical/Biochemical
Signs of
Hyperandrogenism
TWO OF THE
FOLLOWING
1.Oligo/Anovulation
2.Clinical/Biochemic
al Signs of
Hyperandrogenism
3.Polycystic Ovaries
on USG
MUST INCLUDE
ALL
1.Ovariam
Dysfunction
2.Polycystic Ovaries
On USG and
Androgen Excess
6Figure 2 : CRITERIA OF PCOD
In UK –PCOs  is diagnosed by ultrasound findings  plus
symptoms (Obesity, hyperandrogenism, menstrual cycle disturbances)
and  elevated serum concentration of testosterone/LH.In North America
–Hyper androgenism plus menstrual cycle disturbances favour PCOs. In
our country, PCOs is usually diagnosed by morphology seen in USG.
7    PCOS could be divided in 4 types
1. Phenotype A: Menstrual disturbances plus symptoms
hyperandrogenism (Classical Symptoms)
2. Phenotype B : Menstrual irregularity with hyperandrogenism
3. Phenotype C: Hyperandrogenism with ovulatory PCOS.
4. Phenotype D: Menstrual irregularity + PCOS also called non
hyperandrogenism PCOS.
PREVALENCE
PCOS is the most common gynaeocological condition affecting 5
to 10% of women in their reproductive years. It affects 20% of female
population without any signs and symptoms. It is expressed some time
during their fertile period.
8AETIOLOGY
The underlying cause of PCOS is unknown. However, there is
increasing evidence of genetic factors. It is a multifactorial disease. It is
well documented by aggregation of the syndrome within the families.
Increasing evidence has been noted between affected individuals and
their sisters and mothers. It has been proved that it is transmitted as
Autosomal Dominant. Environmental factors are also play a role in
PCOS. It may be due to exposure of androgens during the fertile period.
Identification of candidates with PCOS is a large research focus. It helps
us for diagnosis and management of PCOs. It tells about the genes
regarding androgen synthesis and insulin resistance. Experiment in
Animals showed that exposure of fetus to excess androgens in uterus
lead to these manifestations. PCOS is characterized by chronic
anovulation. Ultrasound is the major tool for diagnosing PCOS. About
25% of normal women will demonstrate ultrasound findings typical of
polycystic ovaries. Patients on oral contraceptive pills will also have
polycystic ovaries.
9Figure 3: Relationship between PCOs and metabolic syndrome
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PATHOPHYSIOLOGY
Figure 4: Pathophysiology of PCOs
There are four important pathophysiology in PCOS.
1. Abnormal ovarian morphology
2. Ovarian Androgen production
3. Hyperinsulinemia
4. Excess serum concentration of LH.
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ABNORMAL OVARIAN MORPHOLOGY
6-8 times more preantral and small antral follicles are present in
the polycystic ovary. The Follicles are arrested in development size of
about  2-9  mm.  There  is  slow  rate  of  atresia.  They  are  sensitive  to
exogenous follicle stimulating hormone. There may be enlarged stromal
volume. Total ovarian volume greater than 10cc is seen. Excess
androgen play a  major role in abnormal ovarian morphology. Primary
follices develop into the stages of preantral and small antral follicles in
the presence of excess androgens. Follistatin, epidermal growth factor,
androgens and antiapoptotic factors play a role in arrested growth of
follicles. These give the appearance of typical polycystic ovarian
morphology.
OVARIAN ANDROGEN PRODUCTION
Ovarian androgen production is the heart of PCOS. Androgen
levels are typically elevated in PCOS. Progesterones levels are low due
to anovulation. Both Luteinizing hormone and insulin play a key role in
androgen excess.
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Insulin Resistance
Women with PCOS have higher degree of insulin resistance with
compensatory hyperinsulinemia. Patients with PCOS have post receptor
uptake defect of glucose transport. Obesity is a major cause of PCOS.
They have hyperinsulism leading to anovulation and hyperandrogenism.
Excessive serum concentration of LH are detected by blood
sampling   on  2nd day of menstrual cycle. Increasing concentration is
seen in lean PCOS. FSH level  is not suppressed.
Homa IR Index
1. Homa model is used to yield an estimation of insulin
sensitivity and Beta Cell function from fasting plasma insulin
and glucose concentration.
2. Insulin resistance is a  state in which  the normal concentration
of insulin produce a subnormal biological response.
13
Uses
1. It assesses the risk of development of Diabetes.
2. It allows assessment of inherent beta cell function and insulin
sensitivity.
3. It characterizes those with abnormal glucose metabolism.
4. It can be used to assess the response to diet or oral drug
therapy.
Limitations
1. Insulin glucose homa model cannot be used in those taking
exogenous insulin.
2. Homa IR calculation version 2.2 accepts  values in the
following ranges  of plasma insulin 2.9 to 57ml and blood
sugar fasting 54.12 to 450 (mg/dl). Homa IR calculation is not
possible if values are outside these ranges.
14
LH and FSH
Figure No. 5 : Menstrual Cycle
LH and FSH that encourage ovulation .LH and FSH are secreted
by Pituitary gland.  At the early follicular  phase LH and FSH levels  are
usually range between 5 to 20 mIU/ml. During follicular phase most
women have equal amount of LH and FSH. Before 24 hrs of ovulation
LH surge occur, in which the amount of LH increases to about 25 to 40
mIU/ml.  LH levels are returns back when follicle ruptures.
Women with PCOs have LH levels 2 to 3 times that of FSH .They
have elevated LH, FSH ratio. This elevated LH to FSH ratio disrupts
ovulation. It is important in the diagnosis of PCOs. 40 to 50% of women
15
with PCOs have excess serum concentration of LH. High LH
Concentration are more commonly seen  in lean women than obese
.There is  intrinsic inhibition of FSH  may  present.
Pathogenesis of PCOD
Figure 6: Pathogenesis of PCOD
Polycystic  ovaries  develop  when  the  ovaries  are  stimulated  to
produce excess amount of androgenic hormone. The most important
hormone is testostosterone with genetic susceptibility. The syndrome is
popularly called as polycystic ovaries due to common sign in
ultrasound. The follicles developed from primordial follicles. The
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development has stopped at early antral stage due to disturbed ovarian
function. The folliciles may be oriented along the peripheries of the
ovary as a string of pearls on USG.
Women with  PCOs have increased frequency of hypothalamic
GNRH Pulses which inturn results in increase in LH & FSH Ratio. Most
of the women with PCOs have insulin resistance and are obese. Elevated
insulin level in PCOs causes abnormalities in hypothalamic pituitary
ovarian axis that leads to PCOD. Hyperinsulinemia increases GNRH
pulse frequency which in turn increases LH over FSH. It also increases
ovarian androgen and decreases follicle maturation. Insulin resistance is
common in obese and lean. Excess adipose tissue in obese women
creates excess androgens which is responsible for virilisation.
17
Clinical Features
  PCOs+Hyperinsulinaemia+Central Obesity
Ovarian androgen Production +Serum Beta
HCG +Free Testosterone+5-Alpha Reductase
? More FSH needed for ovulation induction
? Greater tendency to multi follicular response
? Inferior pregnancy and miscarriage rates
? Hirsutism
? Acne
18
PCOS exhibits with different clinical features with variable
presentation.  By knowing the clinical features of particular patients, it
helps the gynaecologist during workup , initial management and long
term health risk.
Menstrual irregularity
The most common clinical presentation is oligo/amenorrhoea
hence ovulation is inhibited. So it is usually associated with infertility.
Patient usually attains menarche at right time followed by amenorrhoea
associated with stressful life events. Unopposed estrogen may be
associated with heavy bleeding that may cause endometrial hyperplasia.
Period of amenorrhea is usually associated with elevated levels of LH
with decreased levels of FSH. Serum prolactin and serum oestradiol
level may be within normal value. The most important symptom is
oligomenorrhea. There is hyperandrogenism followed by irregular
ovulation. In PCOS, most of the patients have amenorrhea (47%) normal
cycles (29%) Polymenorrhoea (2.7%). Patients with PCOS have prior
irregular cycles may develop regular cycles as age advances. There may
be decrease in antral follicle count.
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In gynaecology outpatient department most of the patients have
oligomenorrhoea. Menstrual disturbances are associated with obesity,
insulin resistance and  elevated androgens. Elevated LH, increases the
ovarian volume. Regular cycles are present is women with PCOs if
Body Mass Index (BMI) is less.
HYPERANDROGENISM
Hyperandrogenism is manifested clinically by hirsutism, acne and
alopecia. Lab test in PCOS reveals hyperinsulinemia and
Hyperandrogenism.  Predominant symptom based on American society
definition is symptoms of hyperandrogenism. Patients with insulin
resistance may have acanthosis nigricans .
Hirsutism
Figure 7: Ferriman-Gallwey score
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In  female  hirsutism  is  male  distribution  of  hair  pattern.  The
number of hair follicle do not vary. The quality, length, diameter and
pigmentation varies. It may be difficult to identify where normality ends
and hirsutism begins. The most important androgen is DHTS,which  is
responsible for hirsutism features. PCOS is most common cause of
hirsutism. The score of 6 -8 according to Ferriman-Gallwey score is
suggestive of hirsutism ,which uses  9 areas.
 In our country, hirsutism is considered if the score is 8 or above.
Other causes of hirsutism are thyroid dysfunction, androgen secreting
tumours of ovary and adrenals. Patients with hyperprolactinemia and
acromegaly also present with hirsutism
ACNE
Figure 8: ACNE
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          Most of the PCOS patients also have acne. The controversy is also
patients who have acne have PCOS. The most important culprit here is
androgen which causes enlargement of sebaceous glands. Further
enlargement sebaceous gland is caused by dihydrotestosterone which is
active metabolite of androgen. The enlarged glands favour the growth of
priopionibacterium . The bacterium which digests the sebum and makes
it more viscous and stimulates inflammation. Comedons are the  initial
lesions of Acne. Distrupted follicles release inflammatory mediators into
the dermis, resulting   in papule, pustule  and  cyst formation.
 Usually  acne develops on face occasionally on back and  chest.
The  lesions  are  tender  and  heal  by  scarring.  Some  studies  say  the
relationship between severity of acne and androgen levels.
Scalp alopecia
Hair loss caused by PCOS called known as Androgen Alopecia. It
is progressive patten of loss of scalp terminal hair without scarring. Hair
loss is diffuse usually in the crown. Frontal hairline is usually preserved
Although many hormones play role in androgen alopecia the main
hormone is dihydrotestosterone.
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Acanthosis Nigricans
Figure 9: Acanthosis Nigricans
5% of PCOS have aconthosis nigricans. It is a skin manifestation
leads to dark velvety appearance due to keratin deposition and
pigmentation. The usual sites are nape, neck, axilla, under the breast.
These  are skin manifestations due to insulin resistance.
Clitromegaly
Goldzieher and Axelrod published a landmark review of the
symptomatology and biochemical features of 1079 cases of surgically-
proven PCOs and described a 21% incidence of mild virilization. PCOS
usually manifest with mild degrees of clitromegaly. If there is
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significant clitromegaly features  of  virilisation is looked for. If patient
has adrenal or ovarian androgen secreting tumours  there is rapid onset
of virilisation with frontal balding, deepening of voice, broadening of
shoulders, decrease in breast size and loss of vaginal rugae.
Hyperandrogenism with Hyperinsulinaemia
Hyperandrogensim is  the most troubling symptom in PCOS.
There is hyperinsulinism contributing to hyperandrogenism . There is
great difficulty in measuring insulin resistance .Taking glucose sample
frequently is difficult. Fasting blood glucose level is simple clinical tool.
It has a great disadvantage to measure glucose level at single time .Some
prefer to measure fasting blood sugar and 60 minute  serum insulin.
Usually the insulin resistance varies during female life time, with
increasing age androgen level and insulin resistance increases.
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Obesity
Obesity is the major cause of PCOD. Obesity increases the  risk
of PCOD by several factors. Obesity decreases Sex Hormone Binding
Globulin and increases free testosterone and oestradiol. Dyslipidaemia
in obesity which causes Coronary Heart Diseases. Insulin resistance  in
PCOD causes diabetes mellitus    . Besides leading to diabetes mellitus
it causes hyperinsulinemia leading to PCOS. Gynaecologist administer
insulin senstiser for ovulation which also decreases androgen levels.
Dyslipidaemia is one of the manifestation of PCOS is due to Insulin
resistance. To asses obesity the most common used ratio is Body Mass
Index which is ratio between weight in kilogram divided by height in
meter2square. BMI normal ranges (19-25), (26-29) is overweight, over
30 is being obese. Obesity is also measure by skin fold thickness and
Waist Hip Ratio.
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LONG TERM RISKS
Figure 10 : Long term risk of PCOs
Glucose Intolerance
Dahlgren has proved that PCOS is the risk faster for Diabetes
Mellitus.Diabetes Mellitus occurs only when pancreas could not
26
produce sufficient insulin. Even in lean PCOS there  is Diabetes
Mellitus and Insulin resistance. Insulin sensitisers should be given to
Insulin resistance patients. In view of reducing long term complications
of PCOS and minimizing cardiovascular risk, insulin senstiser is used.
By giving insulin sensitiser androgen level decreased and complications
of PCOS are decreased. Diabetes prevention programme  campaigned
by using metformin  reduced the  development of frank diabetes.
Cardiovascular Diseases
We have no proven evidence that PCOS is associated with long
term cardiovascular diseases. Even though rising blood sugar and  lipid
profile increases  the  cardiovascular risk,  there is no proven evidence
that PCOS have cardiovascular Diseases. Study was made to prove
Association between cardiovascular diseases and PCOS but there was
no proven evidence.
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Infertility
Figure 11 :  PCOs Infertility
PCOS women present with sub fertility. This is because they have
oligoamenorrhoea and amenorrhoea.  Both of these are associated with
anovolation. By giving insulin senstiser and inducing ovulation, fertility
rate increases.
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Recurrent Miscarriage
Women who have conceived on PCOS have recurrent
miscarriage. The cause of recurrent miscarriage is unknown. But
investigation should done to exclude other causes.
Endometrial Hyperplasia and Adenocarcinoma
Figure 12 :  Endometrial Hyperplasia and Adenocarcinoma
The patients who have PCOS have endometrial hyperplasia &
adenocarcinoma. Dahlgren came to the conclusion that  endometrial
hyperplasia and  adenocarcinoma is   due to unopposed oestrogen. It is
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mandatory to do endometrial sampling on hysteroscopy guided biopsy
for patients with PCOS who have heavy and continuous bleeding.
Depression :
Screening with women with PCOs for depression and anxiety by
history and if identified ,provide appropriate referral.
Sleep Disordered Breathing
Over weight and obese women with PCOs are screened for sleep
disorder.If identified they are diagnosed by  using plethysmography.
Diagnosed patients should be referred for institution for treatment.
Non alcoholic fatty liver disease
There should be awareness of possibility of NAFLD  and  non
alcoholic steatohepatitis in PCOD Patients.
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Differential Diagnosis
a. Oligo/Amenorrhoea from other causes
1. Hypothalamic Amenorrhea
2. Hyperprolactinaemia
3. Premature ovarian failure
4. Drug therapy
b. Hyperandrogenism
1.Late onset congenital adrenal hyperplasia
2.Cushing’s diseases
3.Androgen secreting tumors
4.Obesity for non PCOS reason
5.Non PCOS insulin resistance
31
Ovarian Hyperthecosis
Figure 12 : Hyperthecosis
Ultra sound picture of hyperthecosis showing there is no follicle.
There is a table telling difference between hyperthecosis and PCOD.
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PCOs Hyperthecosis
Inheritance No Autosomal Dominant
Ovarian Size ++ Volume > 10cm + Volume  >7 cm
Follicles Impaired Growth Atretic
Stroma Dense Very Dense
Capsule Thick Thick
Appearance Hirsutism Virilisation
Menses Oligo /Ameno Oligo/Ameno
Hormones Testosterone - N/?
17 OHP- N
LH/FSH  > 3
Testosterone  ? 8 Fold
17 OHP ? twice
Biopsy Theca cyst No
Table 2: Difference between PCOs and Hyperthecosis
Hyperthecosis is a  proliferative condition of ovary where nests of
luteinizing theca cells scattered throughout the stroma. The ovary is
enlarged  due to fibroblast growth. Only differentiation between PCOS
and  hyperthecosis is absence of follicles.  Patients with ovarian
 hyperthecosis high androgen level leading to severe virilisation. These
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patients have Insulin resistance with circulating high insulin levels. Only
the feature of insulin resistance is acanthosis nigricans.
Cushing syndrome
Figure 13 : Cushing’s Syndrome
Cushing’s syndrome is due to excessive cortisol production from
adrenal neoplasm as Adreno Cortico Trophic hormone(ACTH). Over
production  of  ACTH due to primary cause could be pituitary.
Secondary cause may be adenocarcinoma of lung. Clinical feature of
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cushings syndrome are obesity, hirsutism, acne and menstrual
irregularity. They also have moonlike face, buffalo hump, hypertension,
muscle wasting, abdominal striae and osteoporosis. It is usually
manifested by increased free cortisol excretion in urine, loss of circadian
rhythm and failure of suppression of dexamathasone. Ovaries do not
have any features.
Androgen Producing Neoplasm
Very rarely androgen producing tumour are present in ovary and
adrenal gland. The symptoms are very quick in onset and progress with
in months like severe hirsutism, male body habits and clitromegaly.
Because of rapid onset of symptoms it provides clue for diagnosis.
EVALUATION
Diagnostic evaluation
History
1. Menstrual History – includes age of onset of menarche, the
present cycle, duration associated with menorrhoea. Periods of
oligo / amenorrhea.
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2. History of Androgenic symptoms such as hirsutism, alopecia,
duration of onset of virilisation, acne and cliteromegaly.
3. Body mass index, obesity, eating & exercise habits
4. Questions   regarding their lifestyle  including alcohol,
cigarette and smoking
5. History regarding infertility & recurrent miscarriage.
6. Family history of PCOS, Obesity, diabetes and  hyper
androgenism.
Examination
1. To evaluate obesity seeing weight, height, BMI, waist hip
ratio.
2. Assessing hirsutism by ferriman & gallway score in face,
chest & abdomen
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3. General examination includes blood pressure, thyroid
enlargement, abdominal striae, frontal balding, deepening of
voice, broadening of shoulders, decrease in breast size and
loss of vaginal rugae.
4. Pelvic examination: includes ovarian enlargement depending
upon obesity ,loss of  vaginal rugae  and clitoral enlargement
LABORATORY INVESTIGATION
Gonadotropins
Abnormal gonadotropin  secretion  particularly increased LH
concentration is seen in  PCOS. The Patient have decreased or normal
FSH, which causes abnormal LH/FSH ratio. LH and  FSH is measured
by  radioimmuno  assay.  There  was  studies  to  suggest  LH/FSH  >3  as
diagnostic criteria. It was taken as diagnostic criteria in absence of LH
surge during ovulation or menopausal transition. Radio Immunoassay is
based on polyclonal antibodies. The results obtained were not fully
agreed. So the method was changed to immunometric assay.  In
immunometric assay, Monoclonal antibody is targeted to specific sites
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and hence they were not accepted. So they developed new monoclonal
assays. They found that LH/FSH ratio ? 1provided the diagnostic
criteria of PCOS. In lean women there  is rise in LH level which causes
the features of PCOS. But in obese individuals the rise in androgen
levels and insulin resistance leading to PCOS. So BMI play important
role in diagnosing PCOS. Circulating oestradiol  and progesterone could
be measured. Oral contraceptive pills affect gonadotropins levels. By
doing physiological and methodological evaluation of LH, LH could be
used in diagnosing PCOD.
Androgens
There is increase in androgen production. To establish the
diagnosis of PCOs clinical or biochemical signs of Hyperandrogenism
must be  present .Signs of hyperandrognism is hirsutism acne and hair
loss. The measurement  of androgen is most important  step. The
androgen measured are testosterone, Androstenedione,
Dihydroepiandrosterone, Dihydroepi androsterone sulphate. They are
produced from adrenal cortex and  conversion of hormones by ovarian
theca cells.
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In premenopausal woman Dihydroepiandrosteronesulphate is
produced by adrenal cortex. It is in free from without producing any
virilisation.  Dihydroepiandrosterone sulphate has  two sources by ovary
and adrenal cortex. Androstenedione is produced by 1) ovary 2) Adrenal
cortex 3) from peripheral conversion of  DHEA. Under the LH
stimulation with negative feedback of oestradiol  ovaries produce
Androstenedione and testosterone. There is diurnal variation of
Androstenedione. Diurnal variation is due to adrenal contribution and
variation in ovarian contribution due to altered menstrual cycles. But it
increased in PCOS.
Testosterone is most important androgen in PCOS and   is
produced by adrena,l ovaries and peripheral conversion from
circulation.Testosterone is converted to active Dihydrotestosterone by
?? reductase  in target tissue. It does not affected by dihydrotestoserone
.Many studies concluded  that  testosterone level  is elevated in PCOS.
The  study  says  total  testosterone  is  diagnosis  of  PCOS.  Estimation  of
free testosterone help in  diagnosis of PCOS than bound testosterone.
Female  androgenism is measured by Free Androgen Index. It is most
widely used to assess female androgenism.   Sex Hormone binding
globulin  could also be used to  diagnose PCOS. Sex Hormone Binding
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globulin is decreased in PCOS. Testosterone binds tightly with Sex
Hormone Binding globulin. In PCOS increased circulating insulin level
decreases Sex Hormone Binding globulin with elevated Free Androgen
Index.
Antimullerian hormone
Figure 14: Multiple antral follicles
Anti mullerian Hormone is produced by growing antral follicle.
This hormone is widely used invitro fertilization to know the Antal
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follicale count. AMH helps for the growing follicle. AMH has high
specificity  in  diagnosing  PCOS.  AMH is  elevated  PCOS.  It   is  used  in
research purpose of PCOS not yet established for diagnosis.
We can investigate follicle reserve in PCOS. Since Antral follicle
count is increased in PCOS AMH is measured. AMH could be most
reliable marker of PCOS. AMH is used to research purposes but not
established for lab diagnosis.
Laboratory test to exclude other causes of amenorrhoea and
hyperandrogenism
Test To exclude When to perform
FT4 Thyroid Diseases All cases
Thyroid stimulating
hormone
Pregnancy If clinical
suspiciousun
unplained low
LH/FSH, TSH Hyperprolactinemia All cases
Human Chorionic Congenital Adrenal
Hyperplasia
If testo sterone >
4nmol/l
Prolactin Cushing syndrome
41
PCOS occurs usually in  reproductive age group. 10% of
reproductive age group is  affected by PCOS. Anovulation is usually
caused  PCOS.  PCOS  is  diagnosed  by  menstrual  disturbances  with
Anovulation   and  laboratory signs of hyperandrogenism. Other causes
of menstrual disturbances is hyperprolactinemia. It  incidence could be
high as 17% in PCOS. In hyperprolactinemia also there is elevated
androgen levels.
Figure 15 : Prolactin secretion
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In  33%of  PCOS  has  elevated  prolactin.  It  may  be  due  to
lactotrope stimulation by chronic oestrogen exposure. Prolactin is
anterior pituitary hormone. It is under chronic suppression due to
dopamine produced in hypo thalamus reaches anterior pituitary via
pituitary portal circulation. When the suppression is inhibited secretion
increases. Prolactin has circardian rhythm. It alters throughout the cycle.
So it should be measured at least twice to make the diagnosis.
Hyperprolactinemia is caused by pregnanc,y lactation, stress, eating and
thyroid disorder. So the cause of hyperprolactinemia is considered
before  making  diagnosis  of  PCOs  .  Most  common  cause  of
hyperprolactinemiea is pituitary adenoma. Elevated levels of prolactin
decreases gronadrotropin secretion which  causes anovulation and
alteration of menstrual cycle.
Estrogen causes high levels of prolactin which is invariably
present in PCOS. Thyroid diseases also cause irregular cycles.
TSH Levels in PCOs
Thyroid  dysfunction  is  present  in  PCOS.  PCOS  symptoms  are
aggravated by hypothyroidism. SHBG levels decreased in
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hypothyroidism. This causes increase in free testosterone which causes
hyperandrogenism. Gonadotropin levels are decreased in
hypothyroidism which alters oestrogen and progesterone levels leads to
infertility.
             A study conducted on 2009 of 337 women with PCOs .All
women were assessed  with key markers of  PCOs .The study said that
women with PCOs has lowest levels of insulin resistance also had
lowest TSH values.Womens with highest TSH Levels tend to have most
severe insulin resistance. Intrestingly  it was not related to weight.Sub
cilinical hypothyroidism causes insulin resistance in female with all
weight categories.The study concluded that TSH Level above 2 mIu/l
was associated with insulin resistance in PCOs.
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PCOs Low Thyriod
Difficulty in
losing weight
Yes Yes
Hair thinning Yes Yes
Depression Yes Yes
Difficulty in
getting pregnant
Yes Yes
Irregular
menstrual cycles
Yes Yes
Masculinisation Yes No
Cold
Temperature
No Yes
Blood Sugar
Level
Yes No
Table showing difference between hypothyroid and PCOD
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Another study on women with PCOs found  association between
TSH,  insulin resistance and androgen parameters. They reported that
those who had TSH greater than 2.5 mIu/l had higher BMI ,higher
fasting insulin levels and higher total testosterone.
Ovarian volume in Hypothyrodism
PCO like picture is induced by hypothyroidism .In
hypothyroidism causes the deposition of mucopolysaccharides within
various organs. Materials are also deposited in ovary. This hampers
ovarian function and hormone synthesis resulting in disrupted menstrual
cycles.
             The study was conducted in 2011,Effect of hormone
replacement therapy on ovarian volumes and androgen hormones with
untreated primary hypothyroidism. The study discovered that providing
thyroid replacement therapy reduces the size of ovaries and improves
TSH, Prolactin, estradiol and testosterone.
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ULTRASOUND IN PCOS
Figure 16: USG image of PCOs
            For Diagnosis PCOs both TVS and TAS could be used. There
are many USG criteria for diagnosing PCOD. The universally accepted
 criteria (i) increase size of volume due increase is number of follicles
 (2) increasing stoma volume. First real time USG was used by swanson
et  al  3.5  MHZ  to  describe  of  PCOS.  Before  this  it  was   believed   tiny
cyst or follicles could  be seen in USG. Both follicles number and
increasing  stromal volume was not recorded.
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These come to end after high resolution USG. USG did not make
diagnosis of  PCOD. But gives a detailed appearance  of Ovary in
PCOD. Adams et al described TAS to diagnosis PCOD. He said  atleast
10 follicles in one plane, around a dense core of ovaries  stoma. Adam
criteria was used thereafter  for diagnosis PCOD.
Transvaginal USG
TVS is very useful  in diagnosis of  PCOS . TVS has greater and
better resolution than TAS. TVS is better resolution and avoids full
bladder. Ovaries could be visualized better and structure of ovary  could
be studied properly with TVS. In obese patient TVS is better choice.
TVS is better because of (i) high resolution (2) less examination depth
(3) Ovaries  are close to vagina and  uterus (4) presence of less fatty
 tissue.
USG Criteria of PCOS
1. For diagnosis PCOS there should be 12 or more follicles size
about  2- 9 mm in diameter and increase ovarian volume. If
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the cycle has dominant follicle or  corpus luteal cyst the USG
should be postpond to next cycle.
2. Measurement of Ovarian volume place key role in PCOD.
3. Presence of one criteria is sufficient   to diagnosis of PCOD.
4. This is not true if women taking OC pills   because size of
ovary decreases.
5. If ultrasound pictures show PCOS but in absence of
ovulation orhyperandrogenism diagnosis  of PCOs should
not be consider ed  until more is known about this.
6. USG helps to measure ET
Technical Recommendation
1. USG is operated by trained person.
2. TVS is preferred than TAS especially in obese patients
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3. If patients have regular cycles should be followed up in early
follicular phase.
4. If patients is Amenorrohea give her withdrawal bleeding and
then do USG.
5. Presence of dominant follicle or corpus luteal cyst postpond
the USG in next cycle.
6. Ovarian volume must be estimated
7. Follicle number should be evaluated a longitudinal,
transverse and AP cross sections.
Examination of Polycystic Ovary
It is very crucial to identify  two ovaries separately. Maximum
diameter is measured in all three planes. Calculation of  ovarian volume
in difficult because of irregular shape of ovary. Because of overlying
sigmoid  colon in  side of left ovary,it  is difficult to calculate ovarian
volume.
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Internal Features of PCOS
? Follicle size and Number
? Technical  aspects
while describing  polycystic Ovary, a oocyte containing  Follicle  was
observed . In earlier it is believed that cyst are measured not follicle.
? Ovaries are measured in all views and number of follicles  are
also measured.
? TVS is used to measure size and number of follicles. The
follicle are measured in all 3 diameters. PCOS patient have
follicles  of between 4 and 10 mm size.
Stroma volume and Echogenicity
Increase in stromal volume is not a good indicator of Pcod. TVS
helps   to identify stromal thickness. Stormal thickness difficult to
measure and have  subjective variation. Measuring  ET is easy to
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measure. Measuring stromal  thickness along with follicle size and
number is useful to diagnosis PCOS.
TAS, TVS, or both
Trams abdominal scan in used in virgin and those who did not
prefer TVS.TVS help us to  visualize ovaries better than TAS. TAS
requires full bladder to visualize ovaries .Overfilled bladder gives false
positive  results due to compressing ovaries and falsely    increasing
length . Ovarian  size is  measured after  partial micturition . Ovaries are
usually found in near the ureters and iliac vessels.
TVS is best used to diagnosed  PCOS. PCOS is  diagnosed in
30% of women with TAS and 70%  of  women in TVS.
Management
1. Management of presenting symptoms
2.  Life style modification
3. Weight reduction
4. Protect fertility
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5. Prevent from endometrial hyperplasia
6. Prevent from Cardiovascular problems
7. Frequent screening for  Diabetes Mellitus
8. Contraception
9. Treatment  of Complications
10. Cyclical progesterone therapy
11. Fertility treatments
12. Antiandrogen therapy
 13. .Insulin senstising therapy
Follow –up
1. Regular health checkup
2. Weight, BP, FBS, Lipids, (Breast examination) cervical
smear, mammogram etc.
3. Contraception review
4. Follow up evey 3-6 months of Antiandrogen therapy.
5. Look for endometrial hyperplasia in Anovulatory
 dysfunctional uterine bleeding.
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Gulekli  Betal study found that hirsutism was higher in adult
group by 15%. Menstrual irregularity was higher in adult group
presenting with oligomenorrhoea.  Body mass Index was higher in adult
group.  He found that there was positive correlation  between ovarian
volume, serum LH & total testosterone.
Robinsonsetal  et al  proved LH concentration  and LH / FSH
ratio was higher in patients  with PCOS similarly testosterone was also
higher in patients with PCOS.
Balen AH al  studied about ultrasound features of PCOD. When
ultrasound features  suggest PCOD there is elevated  LH concentration.
Dewailly Detal  proved   that  there  was  no  relation   between   LH  and
GNRH in cases with PCOD.
Clayton  RN  et  al  said the ultrasound  features are  present in
 90% of PCOS. Same picture occurs in normal women about 20%. So
only USG could  not be taken for diagnosis of PCOD.
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MATERIALS METHODS
Source of data
This study was carried  from December 2015 to December 2016
on patient attending gynaecology outpatient department  at Stanley
Medical College and Hospital.
Methodology
1. 50 patients were studied in between ages  of 18-35 years
 attending   gynecology op with PCOD in ultrasound and
clinical features.
2. Written informed consent was obtained.
3. History and clinical examination was done.
4. Performa was filled.
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5. Patient who are excluded from study are those  were on
treatment for infertility and  hormonal therapy.
6. History was taken  in detailed manner regarding
oligomenorrhoea, amenorrhoea and  infertility.
7. Clinical finding was recorded   including  hirsutism, acne,
alopecia, acanthosis nigricans and obesity.
8. Height and  weight measured in OP, with help of it BMI  was
calculated.
9. Blood test were done in earlyfollicular phase on day  3 for
serum  LH, FSH, total testosterone, AMH, HOMA IR Index.
It is done electro hemilluminiscence  immune assay in
Stanley  Medical College.
Trans vaginal  scan was done. If  difficult arises,  ovary  is traced
in relation to iliac vessels . Following parameters were located.
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1. Patients with PCOD have atleast 12 or more follicles.  Follicles
should measure 2-9 mm in diameter.
2. Ovarian volume is measured with  prolate  ellipsoid method
= 0.5 x length x breath x thickness > 10 cms3
Hisutism was examined and graded  by  modified ferriman –
gallwey score. Patient with score > 8 was hirsutism.
Statistical Analysis
The data is entered  and calculated using SPSS version  and
software. The statistical significance will be tested. Mean and standard
deviation  were expressed using continuous variables as  BMI, LH,
FSH,  LH/FSH,  AMH,  Home  IR  Index,  sum  LH,  /  FSH,   menstrual
 irregularity, hirsutism , acne, , Ovarian volume, pearson correlation and
coefficient calculated.
Relationship between LH level,LH/FSH ratio, serum testosterone,
Oligomenorrhea / Amenorrhea,  hirsutism, acne using Bi-serial
correlation coefficient.
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RESULTS
Pie chart showing Distribution of 50 cases of Present
 Study with symptoms
Graph  1: Pie chart showing Distribution of 50 cases of Present
 Study with symptoms
There are only 3 phenotypes of PCOS were seen in present study.
Our study included patients  with USG proven PCOs, the 4th phenotype
could not be seen. Menstrual irregularity ,hyperandrogenism, plus USG
47%
34%
19%
Menstrual irregularity Hyperandrogenism Infertility
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proven PCOS is seen in 36 cases. Hyperandrogenism + PCOs is  seen in
15 cases  and menstrual irregularity + PCOS in  27 cases.
Age Distribution
Graph  2 : Age distribution in patients with PCOD
By age distribution graph the present study have age group
maximum between 20-30 years ( 40 cases). Small group of patients was
less than < 20 years > 30 years. The youngest age of  patient  with PCOs
was 18  and oldest was 35.
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Distribution of Cases according to symptoms
Graph  3: Distribution of Cases according to symptoms
50 Patients were studied, out of this menstrual irregularity- 40
cases, Hyper androgenism- 21 cases, Infertility- 9 cases.
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Menstrual Irregularities
Graph 4 : Menstrual Irregularities
Menstrual Irregularity
The present study was done in 50 patients. The most common
symptom is oligomenorrhoea in  26 cases, the least common symptom is
polymenorrhoea.
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Distribution of Hyperandrogenism
In this study, 21 cases have both clinical and biochemical features
of hyperandrogenism.
Graph 5 : Distribution of Hyperandrogenism
Symptoms of Hyperandrogenism
Hirsuitism is most common presentation of PCOS. Acne is
present in small number. Androgenic alopecia only in one case.
1
8
12
Alopecia
Acne
Hirsutism
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Body Mass Index
Graph 6 : Body Mass Index
The following study showed  over weight was the major cause for
PCOD. Next comes obesity.
Less than 25 body mass index in  6 cases, 25 to 30  in 21 cases,
greater than 30 in  23 cases.
6
21
23
BMI
< 25
25 - 30
> 30
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Serum LH in mIU/ml
Serum LH in mIU/ml
Graph 7 : Serum LH in mIU/ml
In the study, many patients have high LH values. 30 cases have
LH  >  10mIU/ml   and   20  cases  <10mIU/ml.  There  was  positive
correlation between LH, FSH and FT3 and negative correlation between
LH/FSH  and  TSH.
30
20
LH > 10mIU/ml
LH < 10mIU/ml
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LH/FSH
                             Pearson correlation
LH/FSH & FT3 Value= .303* P Value = .033 Highly significant
LH/FSH & TSH Value = -.344* P value = .015 Highly significant
Positive Correlation between LH/FSH & FT3
Negative Correlation between LH/FSH and TSH
LH/FSH ratio
Graph 8 : Serum LH in mIU/ml
? LH/FSH > 3 in  16 cases
? LH/FSH <3 in  34 cases
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Menstrual disturbances in Hypothyroidism
Graph 9 : Menstrual disturbances in Hypothyroidism
Thyroid profile is checked for all cases of PCOS. Those patients
with hypothyroidism have major symptoms of oligomenorrhoea . 17
patients with PCOS have hypothyroidism in our study. They presented
with Oligomenorrhoea.
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oligomenorrhagia
oligoamenorrhoea + menorrhagia
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Prolactin levels
Serum prolactin was checked for all cases. Patients with
hyperprolactinemia had  Oligomenorrohea.
Serum PROLACTIN
                                               PEARSON CORRELATION
Serum
prolactin &
TSH
Pearson
correlation
Value = -.282* P value = .047
Highly
Significant
 There is Negative Correlation between Serum Prolactin and  TSH.
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DISCUSSION
The study is carried out in  50 subject with polycystic ovaries in
USG. As per Rotterdam consensus study, clinical examination were
used.
According to Rotterdam criteria 2003 PCOS is classified in 4
types.
1. Phenotype A :  PCOs + menstrual irregularity +
Hyperandrogensim
2. PhenotypeB  :   Hyperandrogenism + menstrual irregularity
3. Phenotype C :  PCOs + Hyperandrogenism
4. Phenotype D :  PCOs + menstrual irregularity
 My study in  stanley medical College showed only 3 phenotypes .
The commonest phenotype in our study  is phenotype A.
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Dewailly detal said that phenotype D is the mildest form of PCOS
with very little insulin resistance. These patients do not have long term
risk as other phenotypes.
Symptoms of PCOS
In our study there 3 main symptoms are  menstrual irregularity
hyperandrogenism and infertility.
Symptoms of PCOs No  of cases
Menstrual irregularities 40
Hyperandrogenism 21
Infertility 9
History and Clinical Exam
In our study,  amenorrhea was present in  10 cases,  menorrhagia
in  4  cases  oligomenorrhoea  in  23  cases  .  In   the  study  conducted  by
ballenetal of about 1741 cases, 66 patients had  menstrual irregularities.
Only small number  of cases have regular cycles. In study by franks et al
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found oligomenorrhoea in 52% cases.  Gold zieheretal  said that  90% of
cases were menstrual irregularity among them  30 to 40% had
amenorrhoea. Most women with PCOS have abnormal menstrual cycle
.The most common is amenorrhoea anovulation.
Balen
et al
n = 1741
(%)
Franks
et al
n = 300
(%)
Goldzieher
et al n=107
9
(%)
Present
Study
n = 50
Oligomenorrhoea
Amenorrhoea
Polymenorrhoea
Menorrhagia
47
19
12
10
52
28
20
16
29
51
33
22
26
10
1
4
Goldzieher et al found there was Amenorrhoea more than other
menstrual irregularities. Aarti Sharma said that the menstrual
irregularity begins in puberty in the form Oligomenorrehoea,
Amenorrhoea  or polymenorrhoea.  Some patients with PCOS have
normal  menstrual  cycles.   Studies  proved   that    Oligomenorrehoea  is
present in 29-47 of female with PCOS , Amenorrhoea in 19.5% of cases.
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Turhan  No  et  al  conducted study about 125 patients with
ultrasound  diagnosis  of PCOS. 55.2% had menstrual  disturbances,
23.2% had normal irregular cycles  and  50.4% had infertility.
                       Gulekli B et al study found Oligomenorrehoea, in 42.8%,
Amenorrhoea in 20%  and normal cycles in 17.4% of cases.
INFERTILITY
Infertility
Graph 10 : Infertility & Alopecia
18%
82%
INFERTILITY IN CASE OF PCOS
INFERTILITY PRESENT
INFERTILITY ABSENT
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Correlation Value
Approx.
Sig.
Infertility &
alopecia
Phi
Correlation
.305 .031 Highly
Significant
Positive Correlation between Infertility & Alopecia
infertility  and Hirsutism
Correlation Value
Approx.
Sig.
infertility *
hirsutism
Phi Correlation .316 .026 Highly
significant
Positive Correlation Between Infertility  and Hirsuitism
Balenaetal had studied infertility about 20% of cases. Franks et
al  said  that  42%  o  case  had  infertility.  In   the  study  by  Aarthisharma
because of Anovulation 20% of all couples with infertility.
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Hyperandrogenism in PCOs
Balen et al
n = 1741
(5)
Franks et
al n = 300
(%)
Goldzieher
et al n = 107
9 (%)
Present
Study N
= 50
Hirsutism 66.2 64 69 12
Alopecia 6 3 - 1
Acne 35 27 - 8
Acnathosis 3 1 - Nil
Balenetal study showed hirsutism in 66.2% , franks  et al  64%  ,
Goldzieher  et  al   69%   and  in  our  study12%.  Small  percentage  of
hirsutism in our study is due to   Ferriman  gallwey score of   > 8  was
taken  for hirsutism. In all other studies above mention took FG  score of
> 6 for  hirsutism.
The signs  of hirsutism in PCOS beings in Menarche and progress
gradually  and  rarely  accompanied  by  other  signs   of  virilisation.  The
most important clinical indicator of Androgen excess is hirsutism . The
only presence of acne and androgenic alopecia could also be taken for
Androgen excess. But they  have not proved. These are poor markers of
androgen excess.
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Acne
In our study acne as found in 8% of cases. Balen et al had acne
in 35% and 27% of cases, by study of franks et al. Timpatanapong p et
al found in 51 patients  with acne, 19 of them had PCOS.
Androgen alopecia
In our study Androgen  alopecia  is seen one case. Balen et al said
6% of PCOS .patients has androgen alopecia  Ester Cela etal   arrived a
conclusion that clinical hyperandrogenism   presented by   hirsutism,
acne or alopecia . Futterweit et al studied 109 women with alopecia and
said 28% of women have PCOD.
Acanthosis Nigricans
In this study not even a single patient have Acanthosis Nigricans .
Study by Balen et al had 3% of cases.
BMI in PCOS
BMI N = 50
< 25 6
25- 30 21
> 30 23
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In our study most of the cases were BMI  > 30 whose  considered
Obese,  so  obesity  is a major cause  of PCOD. In Balen  et al conducted
a  study  and  found  38%  were  obese  .  Series  by  franks  et  al  and
Goldzieher  et al obesity  is found 35% & 41% respectively. Aarti
Sharma said obesity  was   seen in 10- 65% of women.
PCOS patient have body habitus which is  typical. They are
usually over weight with hirsutism. Some patient do not fit within the
body habitus. They were called lean PCOS.
It  was found that   half  the women PCOS have normal weight  or
lean. Insulin resistance is major role in PCOS. Gynaecologist  disagree
insulin   resistance in lean PCOS. Lean of women also have
dearrangement of insulin level and glucose  metabolism. They did not
express  same degree of  insulin resistance  Vrlikova  published a article
on 2004 about Insulin sensitivity in women PCOS. He said that ovaries
are  sensitive   to  insulin   in  women  with  PCOS  leading  to
hyperandrogenism.
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Kravariti   reported in September 2005 that lean  women will also
have same risk of Cardiovascular Symptoms  as overweight women. He
said  that  all  of  women  with  PCOS  should  be  screened  for  CVS
complication regardless of BMI.
Harmonal Evaluation  of PCOS
Study
Balen
et al  n
= 1741
(%)
Franks
et al
 n = 300 (%)
Rajkhowa Pankaret al
Present
study
n = 50
Elevated serum
LH
40 51 33.6 - 28
Hypothyroidism 26 12 30 - 18
Hyper
prolactinemia
10 8 8 - 8
Hypo
prolactinemia
19 4 8 - 2
In our study  levated serum LH level is seen in  28 cases,
Hypothyroidism 18 cases, Hyper prolactinemia  in 8.  In  the revised
2003 criteria   there is  elevated LH levels  in PCOS  in relation to FSH.
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This is caused by   increase amplitude of LH. PCOS women have
elevated LH levels in 60%  and LH / FSH ratio  in 95% of women. Final
said measurement of LH is not primary tool for diagnosis PCOS. But is
should be used as second parameter for PCOS.
Prolactin
Several diagnostic criteria  was used to diagnose PCOS. Among
this is hyperprolactinemia  is less common cause of menstrual
irregularity. In hyperprolactinemia  patients have elevated androgen
levels.  So Prolactin estimation should be done.
Prolactin  is produced by anterior pituitary under the constant
suppression of  dopamine. Dopamine is produced in hypothalamus . It
reaches anterior  pituitary by pitutary     portal circulation and decreases
prolacltin release. When this cycles is altered hyperprolactin results.
Prolactin values changes thorough out the menstrual cycles. So it is
measured atleast twice. Prolactin is elevated by nipple stimulation,
stress, eating and thyroid abnormalities. Pitutary  adenoma cause
hyperprolactinemia. GrRH is suppressed by prolactin which  casus
various menstrual disturbances.
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Oestrogen causes increase prolactin levels in women with PCOS.
They have high estrogen levels which leads to  increase in a prolactin
levels. This result tell us  PCOS with hyperprolactinemia, other causes
should be ruled  out.
A study was conducted in Puduchery found out that a age
advances there is elevated  levels of TSH in PCOS patients. So PCOD
patients must be evaluated for thyroid  profile.
Ultrasonography
There was no significant correlation between hormonal estimation
and ovarian  volume.
Sikka  P  et  al     conducted study in 100 anovulatory infertile
women with PCOD. Every women had amenorrhea, 70% had hirsutism,
half of them were obese. He did TVS which showed increase ovarian
volume. He concluded there was positive correlation between ovarian
size, LH /FSH and hyperinsulinemia.
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CONCLUSION
This study was conducted in Stanley Medical    College at  North
Chennai in 50 cases with polycystic ovaries and concluded that.
1. PCOS in most common gynecological disorder of age 20 -30
years.
2. Phenotype A is the most common presenting type of PCOS.
3. Menstrual irregularity is the presenting symptom of 41 cases
PCOS.
4. Among the menstrual irregularity oligomenorrhoea is present
in 26 cases.
5. There are many features of hyperandrogenism among this
Hirsutism is present 12 cases.
6. There was no correlation between serum prolactin and PCOs
7. TVS is the most the important diagnostic tool.
8. Serum LH/FSH ratio was secondary tool for diagnosing
PCOs is 28 cases.
9. Obesity and overweight is  a most important modifiable  risk
factor which causes 70% of  cases.
10. The one of the important step is weight reduction.
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PERFORMA
Name :
Age :
Address :
OPD No. :
Chief Complaints :
? Amenorrhea / Olgomenorrhoea / menorrhagia / polymenorrhoe
? Hirsutism
? Infertility (Primary / Secondary)
? Acne
? Alopecia
? Weight gain
Any other complaints
Menstrual History :
Obstetric History :
Past History :
Treatment History :
Family History :
General Examination :
Height : Weight :
BMI :
Breast : Thyroid :
Acne :
Alopecia :
90
Acanthosis nigricans :
Local Examination :
Per Abdomen :
Per Speculum :
Per Vaginal :
Investigations
Serum LH Levels : Miu / ml
Serum FSH Levels : mIU / ml
Serum Prolaction Levels : ne / Dl
Thyroid Function Test : FTS: FT4: TSH:
Ultra Sound :
Right Left
? Ovarian Volume in cm3
? No of Follicles & Size
? Stroma
CONSENT FORM
I agree to participate in the study entitled “Correlation of Clinical
and Biochemical Parameters with Ultrasound Features in 100
Women with Polycystics Ovaries”.
I confirm that I have  been told about this study in my mother tongue
and have had the opportunity to clarify my doubts.
I understand that my participation is voluntary and I may refuse to
participate at any time without giving any reasons and without affecting
my benefits.
I agree not to restrict the use of any data or results that arise from this
study.
Name of the participant:
Sign / Thumb print:
Name of the Investigator : Dr. Indirani.D
Sign of Investigator
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 AÖøÁ ]Qaø\°ß ¬ß¦ ]øÚ¨ø£ ¤.].Hi (PCOD) ußø©ø¯
AÔuÀ ©ØÖ® Cµzu £¶÷\õuøÚ²hß J¨¤kuÀ.
B´ÁõÍº : ©¸.x.C¢vµõo
¬x|ø» £mh ÷©Ø£i¨¦ ©õnÁº
  ©P¨÷£Ö ©ØÖ® ö£sPÒ {»zxøÓ
  Bº.Gì.Bº.G®. ©¸zxÁ©øÚ
  ìhõß¼ ©¸zxÁUPÀ¿¶, ö\ßøÚ.
ö£¯º      Á¯x      EÒÎ¸¨¦  Gs.
 C¢u ©¸zxÁ B´Âß ÂÁµ[PÒ GÚUS ÂÍUP¨£mhx GßÝøh¯
\¢÷uP[PøÍ wºUPÄ® AuØPõÚ uS¢u ÂÍUP[PøÍ ö£ÓÄ®
Áõ´¨£ÎUP¨£mhx.
 {õß CÆÁõ´ÂÀ ußÛaø\¯õPzuõß £[÷PØQ÷Óß. G¢u
PõµnzvÚõ¾® G¢u Pmhzv¾® G¢u \mh]UP¾® CßÔ C¢u B´Â¼¸¢x
Â»QU öPõÒÍ»õ® GßÖ® AÔ¢x öPõs÷hß.
 {õß B´Â¼¸¢x Â»QUöPõshõ¾® B´ÁõÍº GßÝøh¯ ©¸zxÁ
AÔUøPPøÍ £õº¨£uØ÷Põ AÀ»x E£÷¯õQUP÷Áõ Gß AÝ©v ÷uøÁ°Àø»
GÚÄ® AÔ¢x öPõs÷hß GßøÚ £ØÔ¯ uPÁÀPÒ µP]¯©õP £õxPõUP¨£k®
Gß£øu²® AÔ÷Áß.
 C¢u B´Âß - »® QøhUS®  uPÁÀPøÍ²® £¶÷\õuøÚ
¬iÄPøÍ²® B´ÁõÍº AÁº Â¸¨£zvØ÷PØ£ £¯ß£kzvU öPõÒÍÄ®
AuøÚ ¤µ_¶UPÄ® ¬Ê©Úxhß \®©vUQ÷Óß.
 C¢u B´ÂÀ £[S öPõÒÍ J¨¦UöPõÒQ÷Óß. GÚUS
öPõkUP¨£mkÒÍ AÔÄøµPÎß£i {h¢x öPõÒÁxhß B´ÁõÍ¸US
Esø©²hß C¸¨÷£ß GßÖ® EÖv AÎUQ÷Óß.
 EhÀ {»® £õvUP¨£mhõ÷»õ ÁÇUPzvØS ©õÓõÚ H÷uÝ® ÷{õ´SÔ
öuß£mhõ÷»õ AuøÚ öu¶Â¨÷£ß GßÖ® EÖv TÖQÓß.
 C¢u B´ÂÀ GÚUS G¢uÂu©õÚ £¶÷\õuøÚPøÍ²® ]Qaø\PøÍ²®
÷©ØöPõÒÍ {õß ¬ÊÁxhß \®©vUQ÷Óß.
   C¨£iUS
B´ÁõÍ¶ß øPö¯õ¨£®    ÷{õ¯õÎ°ß øPö¯õ¨£®
Name Age Op.No. Ameno Meno Oligo  Poly Infertility Acne Alop Hirsutism BMI USG PCO OV (cm3) LH FSH LH/FSH FT3 FT4 TSH S.Prl.
1 Pavithra 26 9874 No No Yes No No No No Yes 28 Yes 12.46 7.6 4.4 1.7 4.2 0.2 5 9
2 Veena 21 7883 No No No No Yes No No Yes 29 Yes 12.4 25 4.1 6.09 7.4 1.3 3 16
3 Reka 23 1971 No No No No No No No No 30.4 Yes 12.3 28 1.6 15.5 5.6 0.66 0.6 13
4 Swapna 22 7886 No No No No No No No Yes 26 Yes 14.2 13.8 2 6.9 6.4 1.33 0.6 49
5 Munisha 24 9447 No No No No No Yes No No 28 Yes 14 6.7 11 0.6 2.3 1.7 6 13.6
6 Lakshmi 26 3478 No No Yes No No No No No 24.01 Yes 10.2 11.1 2.3 4.82 4.6 2.33 5 0.3
7 Ganga 22 619 No No No No Yes No No Yes 26.3 Yes 19.3 6.3 5 1.2 5.9 2.3 0.6 21
8 Varalakshmi 21 456 No No Yes No No No No No 27 Yes 18.2 7.8 4.6 1.69 1.6 2.3 0.1 21.3
9 Saraswathi 23 7845 No No No No No No No No 19.6 Yes 12.1 12.12 6.3 1.9 4.1 2.4 4.1 15
10 Rajeshwary 22 459 No No Yes No No Yes No No 22.6 Yes 10.5 12 8 1.5 4.3 2.6 4.3 12.6
11 Roja 22 489 No No No No No No No No 25.3 Yes 10.7 4.1 2.2 1.8 4.6 2.5 4.2 23.6
12 Yoga 21 4512 Yes No Yes No No No No No 24.9 Yes 15.2 14.8 4.8 3.08 3.3 4.6 5 45.6
13 Baby 18 7840 No No Yes No No No No Yes 30.2 Yes 20.6 12.4 1.2 10.3 6.2 1.3 1 30.2
14 Rajee 30 4600 No No Yes No No No No No 35.1 Yes 15.6 14.2 7.2 1.9 4.3 3.1 2.2 16
15 Sharmila 32 4661 Yes No No No No Yes No No 27.2 Yes 13 3.2 1.5 2.3 3.1 0.9 3.9 1.6
16 Poonam 30 4666 No No Yes No No Yes No No 27.2 Yes 13.3 3.6 1.7 2.1 3.2 0.8 0.1 19.6
17 Jaya 29 4587 No Yes Yes No No No No No 27.3 Yes 13.2 3.2 1.5 2.1 3.2 0.9 3.9 1.64
18 Divya 29 6488 No No No No Yes No No Yes 23.1 Yes 15.1 16 1.2 13.3 6.6 3.4 4.2 2.3
19 Savitha 32 2346 No No No No No No No Yes 21.7 Yes 16 6.1 8.3 0.73 3.2 1.5 2.1 2.4
20 Sathya 29 6613 No No Yes yes No Yes No No 40 Yes 16 4.1 1.2 3.4 6.9 4.3 9.3 21.3
21 Malini 25 1164 No No No No No No No No 34 Yes 16.2 6.1 2.8 2.1 6.7 3.1 2.1 21
22 Hindu 22 9170 No No Yes No No No No No 20.1 Yes 17.1 8.8 4.1 2.1 4.5 0.8 6.2 26
23 Keerthi 31 78 No Yes Yes No No No No No 31 Yes 10.2 12.3 6.8 1.8 5.2 0.7 4 29
24 Uma 30 4318 Yes No No No No No No No 28.3 Yes 10.6 7.4 3.2 2.3 5.03 0.6 2.2 24.3
25 Ramya 21 4510 Yes No Yes No No Yes No Yes 32.2 Yes 13.2 25.5 4.1 6.08 6.04 0.9 2.1 24
26 Arivu 20 9693 No No Yes No No No No No 21.8 Yes 14.3 6.2 8.6 0.72 3.4 1.4 2.1 24
27 Sulthana 22 2889 No No No No Yes No Yes No 25.8 Yes 16 17.2 2.3 7.4 9.3 1.6 0.4 22
28 Akila 24 8771 No No No No Yes No No Yes 31.2 Yes 12.8 21.2 9.3 2.2 3 0.7 3.2 6.4
29 Narmadha 30 8114 No No No No Yes No No No 25.4 Yes 10.9 11.3 3.2 3.5 1.1 0.6 4.1 21
30 Kavitha 26 6613 No No No No No No No Yes 25.6 Yes 11.6 13.5 4.2 3.21 1.3 1.33 6 26
31 Indhu 24 9170 No No Yes No No No No No 28.4 Yes 12.6 6.8 3.1 2.19 6.2 4.2 4.5 21
32 Keerthana 31 78 No No No No No No No No 28.2 Yes 10.5 17.2 2.2 7.8 9.3 1.2 0.4 23.9
33 Selvi 21 4318 No No Yes No No No No No 27.2 Yes 12.6 11.1 1.2 9.2 6.31 2.2 0.005 28
34 Poonam 31 4600 Yes No No No No Yes No No 20.3 Yes 12.8 14.2 1.6 8.8 4.62 2.1 0.4 23.1
35 Lakshmi 28 4587 No No Yes No No No No No 25.2 Yes 28.8 15.3 4.2 3.6 2.1 2.2 0.6 28.6
36 Durga 30 6488 No No Yes No No No No No 23 Yes 21 13.3 3.2 4.1 4.3 2.3 0.3 27.6
37 Shakila 25 4789 No No Yes No No No No Yes 26 Yes 12.3 15.8 1.3 12.1 1.36 1.2 1.02 26.1
38 Pathima 32 6799 No No Yes No No No No Yes 23 Yes 10.2 17.1 2.2 7.7 2.8 2 1.02 22.46
39 Lekha 23 6971 No Yes Yes No No No No No 27 Yes 14.3 12.2 4.3 2.8 4.7 2.2 3.2 21.4
40 Radha 18 5879 Yes No no No No No No No 20.2 Yes 11.6 10.4 2.8 3.7 6.5 2.3 1.3 21
41 Sowmiya 20 7713 Yes No No No Yes No No No 19.4 Yes 13.2 12.2 6.4 1.9 4.1 2.2 4.1 14
42 Sofia 15 1779 No No No No No Yes No No 22.6 Yes 12.1 12.06 8.5 1.4 4.31 2.6 4.2 12.2
43 Yamuna 32 8639 No No Yes No No No No No 26.2 Yes 10.5 4.2 2.2 1.9 4.2 2.2 4.3 23.3
44 Pavithra 24 9874 No No No No Yes No No No 19.5 Yes 10.78 4.4 2.2 1.9 6.2 0.3 4.2 20.6
45 Geetha 33 4555 No No Yes No No No No No 30.2 Yes 13 5.4 1.6 3.3 4.61 0.6 5 17.2
46 Kalpana 16 1010 Yes No Yes No No No No No 20.6 Yes 12.8 10.3 4.9 2.1 5.1 0.6 4.2 19.6
47 Vaishnavi 23 2000 Yes No Yes No No No No No 24.1 Yes 19.3 11.1 2.3 4.8 4.6 2.3 5 0.3
48 Bhuvana 22 4970 Yes Yes No No yes No No Yes 26.3 Yes 10.4 6.3 5 1.26 5.9 2.3 0.6 21.3
49 Nivethitha 20 1331 No No No No No No No No 29 Yes 18.2 7.4 1.6 4.6 4.26 2.2 2 24.6
50 Madhu 25 6974 No No yes No No No No No 27 Yes 11.2 7.8 4.6 1.6 1.69 2.3 0.1 21.3
